Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ovarian Rejuvenation with PRP and SVF (OVAR-REJUV)
NCT04444245Phase 1Unknown
- Start
- Jul 2022
- Primary completion
- Sep 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous adipose stromal vascular fraction in primary ovarian insufficiency (POI), perimenopause and menopause (3 arms). Primary endpoint: Patient Safety For Procedure at 30 days. Status: unknown.
02
Drugs
autologous adipose stromal vascular fraction
03
Conditions
primary ovarian insufficiency (POI)perimenopausemenopause
Beyond the preview
Go deeper on NCT04444245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04444245.